Used as a key intermediate in the synthesis of pharmaceutical agents, particularly in the development of kinase inhibitors for cancer treatment. Featuring a pyrrolidin-2-one ring substituted with a 3,4-difluorophenyl group at position 4, its structure supports binding to enzyme active sites, enhancing selectivity and potency. Also employed in the preparation of neuroprotective compounds and investigational drugs targeting central nervous system disorders. Commonly utilized in medicinal chemistry for scaffold modification to improve metabolic stability and bioavailability.